|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.120 USD | -.--% |
|
-.--% | -22.76% |
| 13/07 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 10/07 | AB Science streamlines its portfolio and refocuses on two molecules |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 32TCr | |||||
| 6.89TCr | |||||
| 971.8Cr | |||||
| 837.22Cr | |||||
| 432.23Cr |
- Stock Market
- Stocks
- AB Stock
- ABSCF Stock
- Charts AB Science
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
